Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs?

Pharmacology and Therapeutics

Volumn 126, Issue 3, 2010, Pages 251-262

  Markus, Regina P ^a   Silva, Claudia L M ^b   Franco, Daiane Gil ^a   Barbosa, Eduardo Mortani ^c   Ferreira, Zulma S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

7 neuronal nicotinic receptor; Aging; Alzheimer's disease; Development; Melatonin; Pineal gland

Indexed keywords

ALPHA BUNGAROTOXIN; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; MELATONIN; NICOTINE; NICOTINIC RECEPTOR;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLINERGIC TRANSMISSION; CHRONOTHERAPY; CIRCADIAN RHYTHM; DEGENERATIVE DISEASE; DRUG EFFICACY; HORMONAL REGULATION; HORMONE ACTION; HORMONE RESPONSE; HORMONE SYNTHESIS; HUMAN; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHOTOPERIODICITY; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR SENSITIVITY; RECEPTOR UPREGULATION;

ALZHEIMER DISEASE; ANIMALS; CHOLINERGIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MELATONIN; RECEPTORS, NICOTINIC; SIGNAL TRANSDUCTION;

EID: 77952958874     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.02.009     Document Type: Review

References (156)

1. Albuquerque E.F.X., Pereira M.E.F., Braga M.F., Alkondon M. Contribution of nicotinic receptors to the function of synapses in the central nervous system: the action of choline as a selective agonist of alpha 7 receptors. J Physiol 1998, 92:309-316.
2. Almeida-Paula L.D., Costa-Lotufo L.V., Ferreira Z.S., Monteiro A.E.G., Isoldi M.C., Godinho R.O., et al. Melatonin modulates rat myotube-acetylcholine receptors by inhibiting calmodulin. Eur J Pharmacol 2005, 525:24-31.
3. Alonso-Vale M.I.C., Andreotti S., Peres S.B., Anhê G.F., Borges-Silva C.N., Lima F.B. Melatonin enhances leptin expression by rat adipocytes in the presence of insulin. Am J Physiol Endocrinol, Metab 2005, 288(2005):805-812.
4. Alonso-Vale M.I.C., Borges-Silva C.N., Anhê G.F., Andreotti S., Machado M.A., Cipolla-Neto J., et al. Light/dark cycle-dependent metabolic changes in adipose tissue of pinealectomized rats. Horm Metab Res 2004, 36:474-479.
5. Arendash G.W., Sanberg P.R., Sengstock G.J. Nicotine enhances the learning and memory of aged rats. Pharmacol Biochem Behav 1995, 52:517-523.
6. Baba K., Pozdeyev N., Mazzoni F., Contreras-Alcantara S., Liu C., Kasamatsu M., et al. Melatonin modulates visual function and cell viability in the mouse retina via the MT1 melatonin receptor. Proc Natl Acad Sci U S A 2009, 106:15043-15048.
7. Barbosa E.J.M., Ferreira Z.S., Markus R.P. Purinergic and noradrenergic cotransmission in the rat pineal gland. Eur J Pharmacol 2000, 401:59-62.
8. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217:408-414.
9. Bencherif M., Lippiello P.M. Alpha7 neuronal nicotinic receptors: the missing link to understanding Alzheimer's etiopathology?. Med Hypotheses 2009, 74:281-285.
10. 3[H]-melatonin to calmodulin. Life Sci 1993, 53:201-207.
11. Bettany J.H., Levin E.D. Ventral hippocampal alpha 7 nicotinic receptor blockade and chronic nicotine effects on memory performance in the radial-arm maze. Pharmacol Biochem Behav 2001, 70:467-474.
12. Blasko I., Stampfer-Kountchev M., Robatscher P., Veerhuis R., Eikelenboom P., Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell 2004, 3:169-176.
13. Boden G., Ruiz J., Urbain J., Chen X. Evidence for a circadian rhythm of insulin secretion. Am J Physiol 1996, 271:246-252.
14. Bordet R., Devos D., Brique S., Touitou Y., Guieu J.D., Libersa C., et al. Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin Neuropharmacol 2003, 26:65-72.
15. Borges-Silva C.N., Takada J., Alonso-Vale M.I., Peres S.B., Fonseca-Alaniz M.H., Andreotti S., et al. Pinealectomy reduces hepatic and muscular glycogen content and attenuates aerobic power adaptability in trained rats. J Pineal Res. 2007, 43:96-103.
16. Borovikova L.V., Ivanova S., Zhang M., Yang H., Botchkina G.I., Watkins L.R., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000, 405:458-462.
17. Bouatia-Naji N., Bonnefond A., Cavalcanti-Proença C., Sparsø T., Holmkvist J., Marchand M., et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 2009, 41:89-94.
18. Braak H., Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging 1997, 18:85-88.
19. Britto L.R., Hamassaki-Britto D.E., Ferro E.S., Keyser K.T., Karten H.J., Lindstrom J.M. Neurons of the chick brain and retina expressing α-bungarotoxin-sensitive and α-bungarotoxin-insensitive nicotinic acetylcholine receptors: an immunohistochemical analysis. Brain Res 1992, 590:193-200.
20. Brusco L.I., Marquez M., Cardinali D.P. Monozygotic twins with Alzheimer's disease treated with melatonin: case report. J Pineal Res 1998, 25:260-263.
21. Brusco L.I., Marquez M., Cardinali D.P. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuroendocrinol Lett 2000, 21:39-42.
22. Buckingham S.D., Jones A.K., Brown L.A., Sattelle D.B. Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol Rev 2009, 61:39-61.
23. Caniato R., Filippini R., Piovan A., Puricelli L., Borsarini A., Cappelletti E.M. Melatonin in plants. Adv Exp Med Biol 2003, 527:593-597.
24. Cannady R., Weir R., Wee B., Gotschlich E., Kolia N., Lau E., et al. Nicotinic antagonist effects in the mediodorsal thalamic nucleus: regional heterogeneity of nicotinic receptor involvement in cognitive function. Biochem Pharmacol 2009, 78:788-794.
25. Cardinali D.P., Brusco L.I., Liberczuk C., Furio A.M. The use of melatonin in Alzheimer's disease. Neuro Endocrinol Lett 2002, 23:20-23.
26. Carneiro R.C., Cipolla-Neto J., Markus R.P. Diurnal variation of the rat vas deferens contraction induced by stimulation of presynaptic nicotinic receptors and pineal function. J Pharmacol Exp Ther 1991, 259:614-619.
27. Carneiro R.C., Markus R.P. Presynaptic nicotinic receptors involved in release of noradrenaline and ATP from the prostatic portion of the rat vas deferens. J Pharmacol Exp Ther 1990, 255:95-100.
28. Carneiro R.C., Pereira E.P., Cipolla-Neto J., Markus R.P. Age-related changes in melatonin modulation of sympathetic neurotransmission. J Pharmacol Exp Ther 1993, 266:1536-1540.
29. Carneiro R.C.G., Markus R.P., Dubocovich M.L. 2-[125I]-iodomelatonin- binding sites in the rat vas deferens. Biological Signal 1993, 2:194-198.
30. Carneiro R.C., Toffoleto O., Cipolla-Neto J., Markus R.P. Modulation of sympathetic neurotransmission by melatonin. Eur J Pharmacol 1994, 257:73-77.
31. Carrillo-Vico A., Calvo J.R., Abreu P., Lardone P.J., Garcia-Maurino S., Reiter R.J., et al. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 2004, 18:537-539.
32. Carvalho L., Gorenstein C., Moreno R., Pariante C., Markus R. Effect of antidepressants on melatonin metabolite in depressed patients. J Psychopharmacol 2009, 23:315-321.
33. Cecon E., Fernandes P.A., Pinato I., Ferreira Z.S., Markus R.P. Daily variation of constitutively activated nuclear factor kappa B (NFKB) in rat pineal gland. Chronobiol Int 2010, 27:52-67.
34. Chan Y.S., Cheung Y.M., Pang S.F. Rhytmic release pattern of pineal melatonin in rodents. Neuroendocrinology 1991, 53:60-67.
35. Coyle J.T., Geerts H., Sorra K., Amatniek J. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. J Alzheimers Dis 2007, 11:491-507.
36. Coyle J.T., Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry 2001, 49:289-299.
37. Cugini P., Touitou Y., Bogdan A., Auzéby A., Pellegrino A.M., Fontana S., et al. Is melatonin circadian rhythm a physiological feature associated with healthy longevity? A study of long-living subjects and their progeny. Chronobiol Int 2001, 18:99-107.
38. Dajas-Bailador F., Wonnacott S. Nicotinic acethylcholine receptors and the regulation of neuronal signaling. Trends Pharmacol Sci 2004, 25:317-324.
39. de Filippi G., Baldwinson T., Sher E. Evidence for nicotinic acetylcholine receptor activation in rat cerebellar slices. Pharmacol Biochem Behav 2001, 70:447-455.
40. de Filippi G., Baldwinson T., Sher E. Nicotinic receptor modulation of neurotransmitter release in the cerebellum. Prog Brain Res 2005, 148:307-320.
41. de Jonge W.J., Ulloa L. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol 2007, 151:915-929.
42. Drijfhout W.A., van der Linde S., Kooi C., Grol B., Westerink B.H.C. Noradrenaline release in the rat pineal gland: the input from the biological clock measured by in vivo microdialysis. J Neurochem 1996, 66:748-755.
43. Dubocovich M.L. Melatonin receptors: are there multiple subtypes?. Trends Pharmacol Sci 1995, 16:50-56.
44. Elgoyhen A.B., Katz E., Fuchs P.A. The nicotinic receptor of cochlear hair cells: a possible pharmacotherapeutic target?. Biochem Pharmacol 2009, 78:712-719.
45. Felix R., Levin E. Nicotinic antagonist administration into the ventral hippocampus and spatial working memory in rats. Neuroscience 1997, 81:1009-1017.
46. Feng Z., Zhang J.T. Melatonin reduces amyloid beta-induced apoptosis in pheochromocytoma (PC12) cells. J Pineal Res 2004, 37:257-266.
47. Feng Z., Chang Y., Cheng Y., Zhang B.L., Qu Z.W., Qin C., et al. Melatonin alleviates behavioural deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J Pineal Res 2004, 37:129-136.
48. Fernandes P.A., Bothorel B., Clesse D., Monteiro A.W.A., Calgari C., Raison S., et al. Local corticosterone infusion enhances nocturnal pineal melatonin production in vivo. J Neuroendocrinol 2009, 21:90-97.
49. Fernandes P.A., Cecon E., Markus R.P., Ferreira Z.S. Effect of TNF-alpha on the melatonin synthetic pathway in the rat pineal gland: basis for a "feedback" of the immune response on circadian timing. J Pineal Res 2006, 41:344-350.
50. Ferreira Z.S., Cipolla-Neto J., Markus R.P. Presence of P2-purinoceptors in the rat pineal gland. Br J Pharmacol 1994, 112:107-110.
51. Ferreira Z.S., Fernandes P.A., Duma D., Assreuy J., Avellar M.C., Markus R.P. Corticosterone modulates noradrenaline-induced melatonin synthesis through inhibition of nuclear kappa B. J Pineal Res 2005, 38:182-188.
52. Fertl E., Auff E., Doppelbauer A., Waldhauser F. Circadian secretion pattern of melatonin in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1991, 3:41-47.
53. Fertl E., Auff E., Doppelbauer A., Waldhauser F. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of L-dopa. J Neural Transm Park Dis Dement Sect 1993, 5:227-234.
54. Fujii S., Sumikawa K. Acute and chronic nicotine exposure reverse age-related declines in the induction of long-term potentiation in the rat hippocampus. Brain Res 2001, 894:347-353.
55. Gallowitsch-Puerta M., Pavlov V.A. Neuro-immune interactions via the cholinergic anti-inflammatory pathway. Life Sci 2007, 80:2325-23259.
56. Ganguly S., Gastel J.A., Weller J.L., Schwartz C., Jaffe H., Namboodiri M.A., et al. Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14-3-3-binding switch in melatonin synthesis. Proc Natl Acad Sci USA 2001, 98:8083-8088.
57. Garfinkel D., Laudon M., Nof D., Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995, 346:541-544.
58. Gilad E., Wong H.R., Zingarelli B., Virág L., O'Connor M., Salzman A.L., et al. Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFkappaB activation. FASEB J. 1998, 12:685-693.
59. Gotti C., Clementi F., Fornari A., Gaimarri A., Guiducci S., Manfredi M., et al. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochemical Pharmacol 2009, 78:703-711. ANO.
60. Guan Z.Z., Zhang X., Ravid R., Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 2000, 74:237-243.
61. Haaque R., Alonso-Gomez A.L., Chaurasia S.S., Luvone P.M. Diurnal regulation of arylalkylamine N-acetyltransferase activity in chicken retinal cells in vitro: analysis of culture conditions. Mol Vis 2003, 9:52-59.
62. Hamassaki-Britto D.E., Gardino P.F., Hokoç J.N., Keyser K.T., Karten H.J., Lindstrom J.M., et al. Differential development of alpha-bungarotoxin-sensitive and alpha-bungarotoxin-insensitive nicotinic acetylcholine receptors in the chick retina. J Comp Neurol 1994, 347:161-170.
63. Jayawickreme S.P., Green W.N., Claudio T. Cyclic AMP-regulated AChR assembly is independent of AChR subunit phosphorylation by PKA. J Cell Sci 1994, 107:641-651.
64. Jean-Louis G., von Gizycki H., Zizi F. Melatonin effects on sleep, mood and cognition in elderly with mild cognitive impairment. J Pineal Res 1998, 25:177-183.
65. Jockers R., Maurice P., Boutin J.A., Delagrange P. Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?. Brit J Pharmacol 2008, 154:1182-1195.
66. Karasek Melatonin, humn aging, and age-related diseases. Experimental Gerontol 2004, 39:1723-1729.
67. Kennaway D.J., Lushington K., Dawson D., Lack L., van den Heuvel C., Rogers N. Urinary 6-sulfatoxymelatonin excretion and aging: new results and a critical review of the literature. J Pineal Res 1999, 27:210-220.
68. Kihara T., Sawada H., Nakamizo T., Kanki R., Yamashita H., Maelicke A., et al. Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity. Biochem Biophys Res Commun 2004, 325:976-982.
69. Klein D.C., Ganguly S., Coon S.L., Shi Q., Gaildrat P., Morin, et al. 14-3-3 proteins in pineal photoneuroendocrine transduction: how many roles?. J Neuroendocrinol 2003, 15:370-377.
70. Korf H.W., Schomerus C., Stehle J.H. The pineal organ, its hormone melatonin and the photoneuroendocrine system. Adv Anat Embryol Cell Biol 1998, 146:1-100.
71. Kunz D., Schmitz S., Mahlberg R., Mohr A., Stöter C., Wolf K.J., et al. A new concept for melatonin deficit: on pineal calcification and melatonin excretion. Neuropsychopharmacology 1999, 21:765-772.
72. Kvetnoy I.M., Ingel I.E., Kvetnaia T.V. Gastrointestinal melatonin: cellular localization and biological role. Neuroendocrinol Lett 2002, 23:121-132.
73. Lahiri D.K., Chen D., Ge Y.W., Bondy S.C., Sharman E.H. Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex. J Pineal Res 2004, 36:224-231.
74. Lee S.J., Liu T., Chattoraj A., Zhang S.L., Wang L., Lee T.M., et al. Posttranscriptional regulation of pineal melatonin synthesis in Octodon degus. J Pineal Res. 2009, 47:75-81.
75. Levin E.D., Bradley A., Addy N., Sigurani N. Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory. Neuroscience 2002, 109:757-765.
76. Ling Z.Q., Tian Q., Wang L., Fu Z.Q., Wang X.C., Wang Q., et al. Constant illumination induces Alzheimer-like damages with endoplasmic reticulum involvement and the protection of melatonin. J Alzheimers Dis 2009, 16:287-300.
77. Liu Q., Zhao B. Nicotine attenuates b-amyloid peptide-induced neurotoxicity, free radical and calcium accumulation in hippocampal neuronal cultures. Br J Pharmacol 2004, 141:746-754.
78. Lopes C., deLyra J.L., Markus R.P., Mariano M. Circadian rhythm in experimental granulomatous inflammation is modulated by melatonin. J Pineal Res 1997, 23:72-78.
79. Lopes C., Mariano M., Markus R.P. Interaction between the adrenal and the pineal gland in chronic experimental inflammation induced by BCG in mice. Inflamm Res 2001, 50:6-11.
80. Lopes J.P., Oliveira C.R., Agostinho P. Cell cycle re-entry in Alzheimer's disease: a major neuropathological characteristic?. Curr Alzheimer Res 2009, 6:205-212.
81. Lotufo C.M., Lopes C., Dubocovich M.L., Farsky S.H., Markus R.P. Melatonin and N-acetylserotonin inhibit leukocyte rolling and adhesion to rat microcirculation. Eur J Pharmacol 2001, 430:351-357.
82. Lück G., Hoch W., Hopf C., Blottner D. Nitric oxide synthase (NOS-1) coclustered with agrin-induced AChR-specializations on cultured skeletal myotubes. Mol Cell Neurosci 2000, 16:269-281.
83. Lukas R.J., Bencherif M. Heterogeneity and regulation of nicotinic acetylcholine receptors. Int Rev Neurobiol 1992, 34:25-131.
84. Luo S., Kulak J.M., Cartier G.E., Jacobsen R.B., Yoshikami D., Oliveira B.M., et al. Alpha-conotoxin AuIB selectively blocks alpha3 beta4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release. J Neurosci 1998, 18:8571-8579.
85. Mahlberg R., Walther S., Kalus P., Bohner G., Haedel S., Reischies F.M., et al. Pineal calcification in Alzheimer's disease: an in vivo study using computed tomography. Neurobiol Aging 2008, 29:203-209.
86. Manchester L.C., Poeggeler B., Alvares F.L., Ogden G.B., Reiter R.J. Melatonin immunoreactivity in the photosynthetic prokaryote Rhodospirillum rubrum: implications for an ancient antioxidant system. Cell Mol Biol Res 1995, 41:391-395.
87. Markus, R., Franco, D.G., Carvalho, L., Gentil, V., & Gorenstein, C. in press. Acute increase in urinary 6-sulfatoximelatonin after clomipramine, as a predictive measure for emotional improvement. J Psychopharmacol. doi:10.1177/0269881109102542.
88. Markus R.P., Ferreira Z.S., Fernandes P.A., Cecon E. The immune-pineal axis: a shuttle between endocrine and paracrine melatonin sources. Neuroimmunomodulation 2007, 14:126-133.
89. Markus R.P., Santos J.M., Zago W., Reno L.A. Melatonin nocturnal surge modulates nicotinic receptors and nicotine-induced [3H]-glutamate release in rat cerebellum slices. J Pharmacol Exp Ther 2003, 305:525-530.
90. Markus R.P., Zago W.M., Carneiro R.C.G. Melatonin modulation of presynaptic nicotinic acetylcholine receptors in rats vas deferens. J Pharmacol Exp Ther 1996, 279:18-22.
91. Martin K., Bégaud B., Latry P., Miremont-Salamé G., Fourrier A., Moore N. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol. 2004, 57:86-92.
92. Martins E., Ferreira A.C., Skorupa A.L., Afeche S.C., Cipolla-Neto J., Costa Rosa L.F. Tryptophan consumption and indoleamines production by peritoneal cavity macrophages. J Leukoc Biol 2004, 75:1116-1121.
93. Masilamoni J.G., Jesudason E.P., Dhandayuthapani S., Ashok B.S., Vignesh S., Jebaraj W.C., et al. The neuroprotective role of melatonin against amyloid beta peptide injected mice. Free Radic Res 2008, 42:661-673.
94. McGehee D.S., Role L.W. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 1995, 57:521-546.
95. McIntosh J.M., Absalom N., Chebib M., Elgoyhen A.B., Vincler M. Alpha9 nicotinic acetylcholine receptors and the treatment of pain. Biochem Pharmacol 2009, 78:693-702.
96. Morley B.J., Garner L.L. Light-dark variation in response to chronic nicotine treatment and the density of hypothalamic alpha-bungarotoxin receptors. Pharmacol Biochem Behav 1999, 37:239-245.
97. Nelson P.T., Braak H., Markesbery W.R. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 2009, 68:1-14.
98. Newhouse P.A., Potter A., Corwin J., Lenox R. Age-related effects of the nicotinic antagonist mecalylamine on cognition and behavior. Neuropsychopharmacology 1994, 10:93-107.
99. Nicolussi E.M., Huck S., Lassmann H., Bradl M. The cholinergic anti-inflammatory system limits T cell infiltration into the neurodegenerative CNS, but cannot counteract complex CNS inflammation. Neurobiol Dis 2009, 35:24-31.
100. O'Neill M.J., Murray T.K., Lakics V., Visanji N.P., Duty S. The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr Drug Targets CNS Neurol Disord 2002, 1:399-411.
101. Obsil T., Ghirlando R., Klein D.C., Ganguly S., Dyda F. Crystal structure of the 14-3-3ζ:serotonin N-acetyltransferase complex. A role for scaffolding in enzyme regulation. Cell 2001, 105:257-267.
102. Ohashi Y., Okamoto N., Uchida K., Iyo M., Mori N., Morita Y. Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer's type. Biol Psychiatry 1999, 45:1646-1652.
103. Olcese J.M., Cao C., Moris T., Mamcarz M.B., Maxwell A., Melissa J., et al. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J. Pineal Res 2009, 47:82-96.
104. Pardo C.A., Martin L.J., Troncoso J.C., Price D.L. The human pineal gland in aging and Alzheimer's disease: patterns of cytoskeletal antigen immunoreactivity. Acta Neuropatholol 1990, 80:535-540.
105. Pavlov V.A., Ochani M., Gallowitsch-Puerta M., Ochani K., Huston J.M., Czura C.J., et al. Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proc Natl Acad Sci USA 2006, 103:5219-5223.
106. Pavlov V.A., Ochani M., Yang L.H., Gallowitsch-Puerta M., Ochani K., Lin X., et al. Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit Care Med 2007, 35:1139-1144.
107. Peck J.S., LeGoff D.B., Ahmed I., Goebert D. Cognitive effects of exogenous melatonin administration in elderly persons: a pilot study. Am J Geriatr Psychiatry 2004, 12:432-436.
108. Pedrazzi P., Pucci L., Zoli M. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol 2009, 78:703-711.
109. Pettit D.L., Shao Z., Yakel J.L. Beta-Amyloid (1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci 2001, 21:RC120.
110. Picciotto M.R., Zoli M. Nicotinic receptors in aging and dementia. J Neurobiol 2002, 53:641-655.
111. Picinato M.C., Hirata A.E., Cipolla-Neto J., Curi R., Carvalho C.R., Anhê G.F., et al. Activation of insulin and IGF-1 signaling pathways by melatonin through MT1 receptor in isolated rat pancreatic islets. J Pineal Res 2008, 44:88-94.
112. Pieri C., Marra M., Moroni F., Recchioni R., Marcheselli F. Melatonin: a peroxyl radical scavenger more effective than vitamin E. Life Sci 1994, 55:271-276.
113. Pontes G.N., Cardoso E.C., Carneiro-Sampaio M.M., Markus R.P. Injury switches melatonin production source from endocrine (pineal) to paracrine (phagocytes) - melatonin in human colostrum and colostrum phagocytes. J Pineal Res 2006, 41:136-141.
114. Pontes G.N., Cardoso E.C., Carneiro-Sampaio M.M., Markus R.P. Pineal melatonin and the innate immune response: the TNF-alpha increases after cesarean section suppresses nocturnal melatonin production. J Pineal Res 2007, 43:365-371.
115. Qi X.L., Nordberg A., Xiu J., Guan Z.Z. The consequences of reducing expression of the alpha7 nicotinic receptor by RNA interference and of stimulating its activity with an alpha7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease. Neurochem Int 2007, 51:377-383.
116. Reiter R.J. The melatonin rhythm: both a clock and a calendar. Experientia 1993, 49:654-664.
117. Reiter R.J., Tan D.X., Cabrera J., D'Arpa D., Sainz R.M., Mayo J.C., et al. The oxidant/antioxidant network: role of melatonin. Biol Signals Recept 1999, 8:56-63.
118. Reiter R.J., Tan D.X., Mayo J.C., Sainz R.M., Leon J., Bandyopadhyay D. Neurally-mediated and neurally-independent beneficial actions of melatonin in the gastrointestinal tract. J Physiol Pharmacol 2003, 54:113-125.
119. Reno L.A., Zago W., Markus R.P. Release of [3H]-l-glutamate by stimulation of nicotinic acetylcholine receptors in rat cerebellar slices. Neuroscience 2004, 124:647-653.
120. Revel F.G., Masson-Pévet M., Pévet P., Mikkelsen J.D., Simonneaux V. Melatonin controls seasonal breeding by a network of hypothalamic targets. Neuroendocrinology 2009, 90:1-14.
121. Rosas-Ballina M., Tracey K.J. Cholinergic control of inflammation. J Intern Med 2009, 265:663-679.
122. Rosołowska-Huszcz D., Thaela M.J., Jagura M., Stepień D., Skwarło-Sońta K. Pineal influence on the diurnal rhythm of nonspecific immunity indices in chickens. J Pineal Res 1991, 10:190-195.
123. Rusted J.M., Newhouse P.A., Levin E.D. Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease. Behav Brain Res 2000, 113:121-129.
124. Sacco K.A., Bannon K.L., George T.P. Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. J Psychopharmacol 2004, 18:457-474.
125. Sampaio L.F., Hamassaki-Britto D.E., Markus R.P. Influence of melatonin on the development of functional nicotinic acetylcholine receptors in cultured chick retinal cells. Braz J Med Biol Res 2005, 38:603-613.
126. Sampaio L.de F., Markus R.P. Melatonin and the time window for the expression of the alpha 8 nicotinic acetylcholine receptor in the membrane of chick retinal cells in culture. Int J Dev Neurosci 2010, 28:245-249.
127. Sargent P.B. The diversity of neuronal nicotinic acetylcholine receptors. Annu Rev Neurosci 1993, 16:403-443.
128. Schrattenholz A., Pereira E.F., Roth U., Weber K.H., Albuquerque E.X., Maelicke A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 1996, 49:1-6.
129. Shida C.S., Castrucci A.M., Lamy-Freund M.T. High melatonin solubility in aqueous medium. J Pineal Res 1994, 16:198-201.
130. Silva C.L.M., Tamura E.K., Macedo S.M.D., Cecon E., Bueno-Alves L., Farsky S.H.P., et al. Melatonin inhibits nitric oxide production by microvascular endothelial cells in vivo and in vitro. Brit J Pharmacol 2007, 151:195-205.
131. Simonneaux V., Ribelayga C. Generation of the melatonin endocrine message in mammals: a review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters. Pharmacol Rev 2003, 55:325-395.
132. Skwarlo-Sonta K., Majewski P., Markowska M., Oblap R., Olszanska B. Bidirectional communication between the pineal gland and the immune system. Can J Physiol Pharmacol 2003, 81:342-349.
133. Sparso T., Bonnefond A., Andersson E., Bouatia-Naji N., Holmkvist J., Wegner L., et al. G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release: studies involving 19, 605 Europeans. Diabetes 2009, 58:1450-1456.
134. Srinivasan V., Pandi-Perumal S.R., Cardinali D.P., Poeggeler B., Hardeland R. Melatonin in Alzheimer's disease and other neurodegenerative disorders. Behav Brain Funct 2006, 2:15-38.
135. Staiger H., Machicao F., Schäfer S.A., Kirchhoff K., Kantartzis K., Guthoff M., et al. Polymorphisms within the novel type 2 diabetes risk locus MTNR1B determine beta-cell function. PLoS One 2008, 3:e3962.
136. Tamarkin L., Baird C.J., Almeida O.F. Melatonin: a coordinating signal for mammalian reproduction?. Science 1985, 227:714-720.
137. Tamura E.K., Cecon E., Monteiro A.W., Silva C.L., Markus R.P. Melatonin inhibits LPS-induced NO production in rat endothelial cells. J Pineal Res 2009, 46:268-274.
138. Tamura E.K., Silva C.L.M., Markus R.P. Melatonin inhibits endothelial nitric oxide production in vitro. J. Pineal Res 2006, 41:267-274.
139. Tan D.X., Manchester L.C., Reiter R.J., Qi W., Hanes M.A., Farley N.J. High physiological levels of melatonin in the bile of mammals. Life Sci 1999, 65:2523-2529.
140. Touitou Y. Human aging and melatonin. Clinical relevance. Exp Gerontol 2001, 36:1083-1100.
141. Tricoire H., Møller M., Chemineau P., Malpaux B. Origin of cerebrospinal fluid melatonin and possible function in the integration of photoperiod. Reprod Suppl 2003, 61:311-321.
142. Turner J.R., Kellar K.J. Nicotinic cholinergic receptors in the rat cerebellum: multiple heteromeric subtypes. J Neurosci 2005, 25:9258-9265.
143. Uchida K., Okamoto N., Ohara K., Morita Y. Daily rhythm of serum melatonin in patients with dementia of the degenerate type. Brain Res 1996, 717:154-159.
144. Verdile G., Fuller S., Atwood C.S., Laws S.M., Gandy S.E., Martins R.N. The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught?. Pharmacol Res 2004, 50:397-409.
145. Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003, 421:384-388.
146. Wang H.Y., Lee D.H., D'Andrea M.R., Peterson P.A., Shank R.P., Reitz A.B. Beta-amyloid 1-42 binds to alpha7 nicotinic acetylcholine receptor with high affinity: implications for Alzheimer's disease pathology. J Biol Chem 2000, 275:5626-5632.
147. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci 1997, 20:92-99.
148. Wu Y.H., Swaab D.F. The human pineal gland and melatonin in aging and Alzheimer's disease. J Pineal Res 2005, 38:145-152.
149. Wu Y.H., Feenstra M.G.P., Zhou J.N., Liu R.Y., Torano J.S., Van Kan H.J.M., et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab 2003, 88:5898-5906.
150. Young J.W., Finlayson K., Spratt C., Marston H.M., Crawford N., Kelly J.S., et al. Nicotine improves sustained attention in mice: evidence for involvement of the alpha7 nicotinic acetylcholine receptor. Neuropsychopharmacology 2004, 29:891-900.
151. Zago W., Markus R.P. Light/dark cycle modulates neuronal presynaptic nicotinic acetylcholine receptors (nAChRs) in rat hippocampus. Biological Clocks - Mechanisms and Applications 1998, 217-220. Excerpta Medica, Netherlands. Y. Touitou (Ed.).
152. Zago W.M., Markus R.P. Melatonin modulation of presynaptic nicotinic acetylcholine receptors located on short noradrenergic neurons of the rat vas deferens: a pharmacological characterization. Braz J Med Biol Res 1999, 32:999-1006.
153. Zawilska J.B., Derbiszewska T., Nowak J.Z. Prolonged exposure of chicks to light or darkness differentially affects the quinpirole-evoked suppression of serotonin N-acetyltransferase activity in chick retina: an impact on dopamine D4-like receptor. J Pineal Res 1997, 22:59-64.
154. Zeitzer J.M., Daniels J.E., Duffy J.F., Klerman E.B., Shanahan T.L., Dijk D.J., et al. Do plasma melatonin concentrations decline with age?. Am J Med 1999, 107:432-436.
155. Zhao Z.Y., Xie Y., Fu Y.R., Bogdan A., Touitou Y. Aging and the circadian rhythm of melatonin: a cross-sectional study of Chinese subjects 30-110yr of age. Chronobiol Int 2002, 19:1171-1182.
156. Zhou J.N., Liu R.Y., Van Heerikhuize J., Hofman M.A., Swaab D.F. Alterations in the circadian rhythm of salivary melatonin begin during middle-age. J Pineal Res 2003, 34:11-16.